Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2015

View Archived Issues

Osaka University starts phase I/II trial of CNT-01 in patients with idiopathic TGCV

Tohoku University, Gunma University and Fuso disclose OPN production inhibitors

Glycemic improvements similar with omarigliptin and sitagliptin in patients with type 2 diabetes

Pediatric schistosomiasis candidate L-praziquantel safe in phase I study in healthy volunteers

New mutation in HNF1B identified in patient with maturity-onset diabetes of the young type 5

Rat forelimb allotransplantation model enables assessment of function

FDA grants fast track designation to Alcobra's metadoxine extended release

Transgenic pigs used to model gestational diabetes

Glide Technologies and Cilian to develop novel solid dose recombinant influenza vaccine

Palatin Technologies and Richter terminate license agreement for bremelanotide

Saniona reports data supporting the use of Tesomet in type 2 diabetes, plans proof-of-concept study

Artificially designed peptide inhibits HIV fusion with improved pharmacological properties

AcelRx sells portion of Zalviso royalty stream to PDL BioPharma

Phase III induction trials of tofacitinib in ulcerative colitis meet primary endpoints

Companies receive funding to advance Ebola programs

Harbour Antibodies signs new licenses to transgenic mouse platforms

Roche reports compounds for the treatment of hepatitis B

Gilead reports topline results from four phase III studies of sofosbuvir/velpatasvir for HCV

Aerie initiates phase III trial of Roclatan

Akari Therapeutics formed to develop treatments for diseases involving complement C5

Plexxikon discloses c-Kit inhibitors

Clinical effect of K-877 may be superior to fibrate drugs on the market

Taro launches Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Pharmaxis reports phase I results for PXS-4728A

LFB's IVIg Iqymune approved in U.K. and Denmark

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...